104 results about "Mimotope" patented technology

The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11Rα and hsp90. Antibodies against such targeting peptides or their mimeotopes may be used for detection, diagnosis and/or staging of prostate or ovarian cancer. In other embodiments, the compositions and methods concern novel type of gene therapy vector, known as adeno-associated phage (AAP). AAP are of use for targeted delivery of therapeutic agents to particular tissues, organs or cell types, such as prostate or ovarian cancer. In still other embodiments, targeting peptides selective for low-grade lipomas may be used for detection, diagnosis and targeted delivery of therapeutic agents.

The invention discloses a method for determining key amino acid of milk allergen epitope, which comprises the following steps of: synthesizing an epitope peptide section according to the primarily determined mimic epitopes area amino acid sequence, and fixing and protecting the epitope peptide section, wherein the C end covalence of the epitope peptide section is combined to an activated fibrous membrane and the N end is acetylized; taking single glycine as a negative control, reacting the synthesized amino acid sequence with polyclonal serum, and determining the main epitope of beta-milk globulin; sequentially substituting each amino acid with alanine or glycine to obtain the amino acid sequence needing to be synthesized; using the obtained amino acid sequence to synthesize the epitope peptide section, and fixing and protecting the epitope peptide section, wherein the C end covalence of the epitope peptide section is combined to the activated fibrous membrane and the N end is acetylized; and taking the single glycine as the negative control, reacting the synthesized amino acid sequence with the polyclonal serum, and determining the key amino acid in milk epitope. The method lays a foundation for the diagnosis and treatment of milk allergy and the detection of an allergen in foods and provides theoretical basis and technical support for the development of hypoallergenic milk.

The invention discloses a CTL (Cytotoxic T Lymphocyte) epitope peptide of a foot-and-mouth disease virus type O as well as a screening method and application of the CTL epitope peptide. The CTL epitope peptide is composed of nine amino acid residues, and the amino acid sequence of the CTL epitope peptide is as follows: Ala-Thr-Arg-Val-Thr-Glu-Leu-Leu-Tyr. The epitope peptide has relatively strong combining capacity with SLA (Swineleukocyteantigen)-I proteins from various strains of swine and can induce cytotoxic immune response so as to be suitable for preparing vaccines for preventing and controlling foot-and-mouth disease viruses of various strains of swine and wide in application range. According to the invention, a CTL simulated epitope peptide of a foot-and-mouth disease virus is combined with a single-chain molecule of SLA-I of six strains of constructed swine in vitro, thus a polypeptide which can be combined with a complex can be screened through mass spectrum measurement; in addition, a simulated epitope peptide which can be induced to generate the immune response capacity of T cells is determined through ELISPOT (Enzyme-Linked Immunospot Assay) detection. The invention provides a method for screening and authenticating the CTL epitope of the foot-and-mouth disease virus in a large scale, and lays the foundation for researching and preparing a multi-epitope vaccine of a foot-and-mouth disease.

The invention discloses type A foot-and-mouth disease CTL (cytotoxic T lymphocyte) epitope peptide and a screening method thereof. The CTL epitope peptide consists of nine amino acid residues, and has an amino acid sequence of Ala-Met-Leu-Arg-Ala-Ala-Thr-Tyr-Tyr. The epitope peptide has stronger combining capability with SLA (swine leukocyte antigen)-?? proteins from pigs with different strains and causees cell toxicity immune response, and is applicable to the preparation of prevention and treatment vaccines for foot-and-mouth disease virus of pigs with various strains and wide in application range. According to the type A foot-and-mouth disease CTL epitope peptide and the screening method thereof, constructed SLA-I single-stranded molecules of pigs with six strains are utilized for in vitro combination with CTL simulated epitope peptide of foot-and-mouth disease virus, polypeptide which can be combined with complex is determined and screened by using a mass spectrum, and simulated epitope peptide which can induce the production of T cell immune response capability is determined through ELISPOT (enzyme linked immunospot assay) detection. The invention provides a method for screening and identifying a large number of foot-and-mouth disease virus CTL epitopes in the future, and lays a foundation for the development of multi-epitope vaccines for the foot-and-mouth disease of pigs.

The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3ε). These molecules compete with CD3ε for binding to a CD3ε binding domain. e.g. a CD3ε binding domain of an antibody, and are capable of detecting antibodies against CD3ε. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3ε antibody purification and the detection of anti-CD3ε antibodies in biological samples.

The invention relates to an antigen epitope of gold staphylococcus virulence factor regulatory protein and its mimic epitope, wherein the amino acid sequence of the antigen epitope is NPTHQLFQFSASDT or SYFERYLYPIKE, the amino acid sequence of the analogue epitope is XPXHHQHXTGFT or SWFDXXLYPXXX, X is any one of the 21 known natural L-type amino acid residue or its D-type isomers. The antigen epitope or its analogue epitope can be applied in preparing staphylococcus aureus resistant medicament.

The present invention relates to peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccines.

The invention relates to staphylococcus aureus FnBPA-A protein mimic epitope peptides having immunizing protection, a mimic epitope peptide composition, and applications of the mimic epitope peptides and the mimic epitope peptide composition. Two immunoprotective mimic epitope peptides provided by the invention have the amino acid sequences respectively shown in SEQ ID NO:1 and SEQ ID NO:2, the mimic epitope peptide composition consists of two polypeptides shown in SEQ ID NO:1 and SEQ ID NO:2, and the mass ratio of the polypeptide shown in SEQ ID NO:1 to the polypeptide shown in SEQ ID NO:2 is 2 to 1. Experiment animal immunoprotective tests show that the two mimic epitope peptides can stimulate a body to produce high-level specific antibodies and have a certain degree of immunizing protection; moreover, the mimic epitope peptide composition has the immunoprotective effect on staphylococcus aureus infection better than that of an FnBPA-A holoprotein. Therefore, the mimic epitope peptides and the composition thereof can be used as effective components for development of multi-epitope vaccines of staphylococcus aureus and prevention of cow mastitis caused by staphylococcus aureus.

Peptidyl sequences, called mimotopes, are disclosed which mimic the binding site of the broadly neutralizing human monoclonal antibody, 2G12, specific for the HIV protein gp120. The mimotopes are identified from a chimeric protein III (pIII) phage display library, each phage containing an additional random 15 amino acids near the N-terminus of pIII. Immunological conjugates of HIV-specific mimotopes that are useful for vaccination against HIV infection are disclosed. Methods for using the mimotopes and their immunological conjugates as part of an HIV vaccine regime, as well as diagnostic tools to perform viral assays, are also disclosed.